Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trial

Overview of attention for article published in Neuro-Oncology, May 2022

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#15 of 4,190)
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (98th percentile)

Mentioned by

news: 44 news outlets
twitter: 5 X users

guideline: 1 clinical guideline source

Readers on

mendeley: 37 Mendeley

So far, Altmetric has seen 5 X posts from 5 X users, with an upper bound of 15,235 followers.

RT @EANOassociation: #Olutasidenib (FT-2102) in patients with relapsed or refractory #IDH1-mutant #glioma: a multicenter, open-label, phase…

Research team reports on new treatment option for brain tumors that relapse or fail to respond to standard of care https://t.co/LVkTnJQAQT https://t.co/l8fpGeS3DX

Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: a multicenter, open-label, phase 1b/2 trial https://t.co/QgerIyfstX #hvhebron #onco [Text complet] @NeuroOnc

RT @EANOassociation: #Olutasidenib (FT-2102) in patients with relapsed or refractory #IDH1-mutant #glioma: a multicenter, open-label, phase…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 1 additional X posts.